Amino acid sequence of the active site of human serum cholinesterase from usual, atypical, and atypical-silent genotypes by Lockridge, Oksana & Du, Bert N.
Biochemical Genetics, Vol. 24, Nos. 5/6, I986 
Amino Acid Sequence of the Active Site of Human 
Serum Cholinesterase from Usual, Atypical, and 
Atypical-Silent Genotypes 
Oksana Lockridge 1'2 and Bert N.  La Du I 
Received 6 Dec. 1985--Final 3 Mar. 1986 
Active-site tryptic peptides were &olated from three genetic types of  human 
serum cholinesterase. The active-site peptide was identified by labeling the 
active-site serine with [3H]diisopropylfluorophosphate. Peptides were puri- 
fied by high-performance liquid chromatography. Amino acid composition 
and sequence analysis showed that the peptide from the usual genotype 
contained 29 residues with the sequence Ser-Val-Thr-Leu-Phe-Gly-Glu- 
Ser-Ala-Gly-Ala-Ala-Ser-Val-Ser-Leu-His-Leu-Leu-Ser-Pro-Gly-Ser-His- 
Ser-Leu-Phe-Thr-Arg. The active-site serine was the eighth residue from the 
N- terminal. The peptide containing the active-site serine from the atypical 
genotype contained 22 residues with the sequence Ser-Val-Thr-Leu-Phe- 
Gly-Glu-Ser-Ala-Gly-Ala-Ala-Ser-Val-Ser-Leu-His-Leu-Leu-Ser-Pro-Gly. 
The peptide from the atypical-silent genotype contained eight residues with 
the sequence Gly-Glu-Ser-Ala-Gly-Ala-Ala-Ser. Thus, the sequences of  the 
atypical and atypical-silent active-site peptides were identical to the corre- 
sponding portions of  the usual peptide. 
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I N T R O D U C T I O N  
H u m a n  serum chol ines terase  (EC 3.1.1.8; acylchol ine  acyl  hydrolase)  is also 
known as pseudochol ines terase ,  bu tyry lchol ines te rase ,  and nonspecific cho- 
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linesterase. The genetic variants of human serum cholinesterase were discov- 
ered after the drug, succinylcholine, gained widespread use as a muscle 
relaxant. It was observed that 1 in approximately 2000 patients was unable to 
breathe for prolonged periods, even hours, after receiving a normal dose of 
succinylcholine (Kalow and Gunn, 1959). Kalow provided an explanation for 
this abnormal response by showing that it occurred in persons having an 
"atypical" form of cholinesterase (Kalow and Gunn, 1957) characterized by a 
reduced affinity for succinylcholine (Hersh et al., 1974). Later, additional 
genetic variants were identified. One of these was the "silent" variant which 
had zero or nearly zero activity (Liddell et al., 1962). 
The properties of the atypical cholinesterase variant could be explained 
by a single amino acid alteration at the anionic site (Kalow and Davies, 1958; 
Muensch et al., 1978; Lockridge and La Du, 1978). However, to date this has 
not been established and no amino acid sequence information for any portion 
of the atypical variant has been published. For the usual cholinesterase the 
total amino acid sequence information published to date is an 11-residue 
fragment from the active site (Yamato et al., 1983). Yamato et al. suggested 
that the single amino acid alteration in atypical cholinesterase was a substitu- 
tion from Glu to His within their 11-residue active-site peptide. The basis for 
their suggestion was the difference in electrophoretic mobility of the active 
site peptides obtained from the usual and atypical cholinesterases. We also 
found that the usual and atypical active-site peptides had different physical 
properties, since they eluted at different positions on HPLC 3 and had different 
solubilities. However, we disagree with Yamato's interpretation that the 
difference is due to an amino acid substitution within the active-site peptide. 
We found that the usual cholinesterase yielded a 29-residue tryptic peptide, 
while the atypical and atypical-silent cholinesterases yielded shorter peptides 
that were not the result of cleavage by trypsin. The sequences of the atypical 
and atypical-silent active-site peptides were identical to the region around the 
active-site serine of the usual form of cholinesterase. 
EXPERIMENTAL PROCEDURES 
Blood Samples .  The source of usual cholinesterase, genotype UU, was 
outdated human plasma, kindly provided by Dr. Harold Gallick of the 
Michigan Department of Public Health, Lansing. The source of atypical 
cholinesterase, genotype AA, was a single female donor with a family history 
3 Abbreviations used: DFP, diisopropylfluorophosphate; MP, monoisopropylphosphoryl; SDS, 
sodium dodecyl sulfate; HPLC, high-performance liquid chromatography; TFA, trifluoroacetic 
acid; HFBA, heptafluorobutyric acid; PTH, phenylthiohydantoin; A, alanine; E, glutamic acid; 
F, phenylalanine; G, glycine; H, histidine; L, leucine; P, proline; R, arginine; S, serine; T, 
threonine; V, valine. 
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of succinylcholine apnea. From her activity of 0.53 ~mol benzoylcholine 
hydrolyzed/min/ml of serum (Kalow and Lindsay, 1955), her dibucaine 
number of 24 (Kalow and Genest, 1957), and her fluoride number of 37 
(Harris and Whittaker, 1961), it was concluded that she had the AA 
genotype. Her AA genotype was confirmed by genotyping three generations 
of family members. Our AA donor underwent plasmaphoresis over a period of 
2 years, until 3.5 liters of plasma had accumulated. Plasma was stored at 
-20°C. The source of atypical-silent cholinesterase, genotype AS, was a 
single male donor who experienced 3hr of apnea after receiving 120 mg of 
suecinylcholine. He had the characteristic dibucaine number (DN 18), 
fluoride number (FN 24), and activity (0.25 ~zmol benzoylcholine/min/ml 
serum) of the atypical phenotype. Genotyping of three generations of family 
members revealed that he was heterozygous for atypical-silent cholinesterase. 
Nine and four-tenths liters of his plasma was collected by plasmaphoresis over 
a period of 3 years. 
Enzyme Purification. The usual cholinesterase was purified by ion- 
exchange chromatography at pH 4 on Whatman DE52, followed by ion- 
exchange chromatography at pH 7, and finally by affinity chromatography on 
procainamide Sepharose 4B (Lockridge and La Du, 1978). The second 
ion-exchange step could be omitted when the purification on the pH 4 
ion-exchange column was 1200-fold or greater. This degree of purification 
was not always achieved, and therefore the second ion-exchange step was 
included. The proeainamide step yielded pure enzyme only if the applied 
enzyme was already at least 1200-fold pure. A total of 100 liters of plasma was 
used. Seven and one-half liters of plasma was processed at one time, with a 
yield of 8 to 12 mg of cholinesterase. On SDS gel electrophoresis the purified 
usual cholinesterase had a major band with a molecular weight of 90,000. The 
only other band visible with either silver staining or Coomassie blue staining 
was a faint dimer band with a molecular weight of 180,000. The atypical and 
atypical-silent cholinesterases were purified by similar strategies. 
Labeling the Active Site. Three to 64 mg of cholinesterase was treated 
with 2 equivalents of [3H]DFP (5.2 Ci/mmol). This amount of DFP brought 
the enzyme activity to zero. The reaction mixture was incubated for 4 days or 
more to achieve "aging." During aging the diisopropylphosphate derivative is 
catalytically converted to the more stable monoisopropylphosphate derivative 
(Berends et al., 1959). It proved advantageous to have the monoisopropyl- 
phosphate derivative because this gave a higher yield of active-site tryptic 
peptide, and it gave a single radioactive peptide. 
Reduction and Alkylation with Iodoacetamide. The aged MP-cholines- 
terase was concentrated to 1 to 5 mg/ml and placed inside a glass screw-cap 
tube. Solid guanidine-HC1 (Schwartz-Mann Co., ultrapure, or Pierce Co., 
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sequanal grade) was added to a final concentration of 6 M, the pH adjusted to 
8.1 with 1 M unneutralized Trizma base, and EDTA added to 4 mM. A 
mininert valve (Pierce Co.) was screwed on the tube and nitrogen bubbled into 
the solution for 1 hr. A freshly prepared solution of 0.7 M dithiothreitol was 
injected through the valve to a final concentration of 4 mM dithiothreitol. 
Nitrogen was bubbled into the solution for an additional 3-hr period. A freshly 
prepared solution of 0.7 M iodoacetamide in water was injected through the 
valve to give a 10% excess of iodoacetamide over total dithiothreitol and 
protein sulfhydryls. The glass tube was wrapped in aluminum foil to exclude 
light and the reaction allowed to proceed for 1 hr while continuing to bubble 
nitrogen. The reaction was terminated by dialysis which was begun immedi- 
ately. It was important to maintain oxygen-free conditions throughout the 
reduction and alkylation procedure to avoid problems later during digestion 
with trypsin. One sample was alkylated with vinylpyridine (Tarr, 1985) rather 
than iodoacetamide, but this was not helpful because it made the protein 
precipitate during digestion. Iodoacetic acid could be used in place of 
iodoacetamide with equally good results. 
Trypsin Digestion. The dialyzed protein in 0.1 M Tris-C1, pH 8.1, was 
digested with trypsin/L-l-tosylamido-2-phenylethyl chloromethyl ketone 
(Worthington Co.) at 37°C for 4 hr. The amount of trypsin was 2% of the 
weight of cholinesterase. A single addition of trypsin was sufficient to achieve 
complete digestion. In contrast to the report of Muensch et al. (1978) we did 
not need to digest longer than 4 hr or make multiple additions of trypsin, nor 
did the sugar chains of cholinesterase present a problem. We believe that these 
differences are due to the fact that we achieved complete reduction of 
disulfides and alkylation of reduced sulfhydryls with our strict anaerobic 
conditions. This made the protein available to trypsin digestion. Cholinester- 
ase with partly intact disulfide bridges could resemble native cholinesterase, 
which is known to be extremely resistant to trypsin (Lockridge and La Du, 
1982), probably because of its 24% carbohydrate content (Haupt e t  al., 
1966). 
HPLC to Purify MP-Tryptic Peptide. A Varian HPLC, Model 5060, 
was used with UV and fluorescence detectors. The MP-tryptic peptide was not 
fluorescent but it had to be separated from a fluorescent contaminating 
peptide. Fluorescence excitation passed through an interference filter which 
had a maximum of 220 nm. Emission passed through a Corning 7-60 glass 
band filter which included wavelengths 300 to 400 nm, with a maximum at 
352 nm. MP-peptide from the usual genotype, UU, was purified as follows: 
(1) HPLC on a Synchropak RP-P column (Synchrom Co., Linden, Ind.) 
eluted with a gradient of 0.1% TFA versus acetonitrile containing 0.075% 
TFA as in Fig. 1 A--65% of the applied counts were recovered; (2) HPLC on a 
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Fig, 1. Isolation of the DFP-labeled tryptic peptide from cholinesterases of various genotypes. A 
1.0-ml portion (5 to 10 nmol) of the 4-hr tryptic digest of the [~H]DFP-labeled, S- 
carboxyamidomethylated cholinesterase was applied to the Synchropak RP-P column (0.41 × 25 
cm) equilibrated with solvent A (0.1% TFA in water). Peptides were eluted with a linear gradient 
increasing in solvent B (acetonitrile containing 0.075% TFA) at a gradient rate of 0.75%/min. 
The flow rate was 1 ml/min. Radioactivity is indicated by asterisks. (A) Genotype UU; (B) 
genotype AS; (C) genotype AA. Protein sylfhydryls in C were alkylated with vinylpyridine, and 
the protein was digested with trypsin and S.  aureus  protease. 
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Synchropak RP-P column eluted with a gradient of 10 mM Na /K  phosphate, 
pH 7.4, versus methanol--62% of the applied counts were recovered; and (3) 
HPLC on a Synchropak RP-P column eluted with a gradient of 0.1% HFBA 
versus acetonitrile--97% of the applied counts were recovered. It was essential 
to use a neutral pH buffer to achieve separation from a fluorescent peptide. 
The third HPLC step was for desalting and also for additional purification. 
The overall yield was 39%. 
The MP-peptide from the atypical-silent genotype (Fig. 1B) was puri- 
fied with the same three solvent systems as the usual cholinesterase peptide. 
The recoveries of applied counts were 34, 48, and 93%, with an overall yield of 
15%. The first HPLC step actually yielded 82% of the applied counts but most 
of these eluted at the solvent front and only 34% eluted with the MP-peptide at 
27 min. 
Conditions for purifying the atypical, AA, MP-peptide were changed 
because this peptide was found to have different solubility properties. It eluted 
in a broad peak over 30 min when 10 mM Na/K phosphate, pH 7.4, was used 
in a gradient with acetonitrile and, furthermore, could not be redissolved in 
TFA after it had been dried in the presence of a large amount of phosphate 
salts. In contrast, the usual MP-tryptic peptide eluted in a sharp peak with this 
same solvent system and was easily dissolved in TFA. The major change in 
HPLC conditions was the use of 0.1 M hexafluoroacetone-ammonia, pH 7.1, 
in place of 10 mM Na/K phosphate, pH 7.4. Hexafluoroacetone (Aldrich Co.) 
has the advantages that it is volatile and transparent at 220 nm (Tarr and 
Crabb, 1983) but has the disadvantages that it is toxic and expensive. The 
atypical (AA) MP-peptide was purified as follows: (1) HPLC on a Synchro- 
pak RP-P column eluted with a gradient of 0.1% TFA versus acetonitrile 
containing 0.075% TFA--recovery of the applied counts was 18%; (2) HPLC 
on a/~bondapak CN column (Waters Co.) eluted with 0.1% HFBA versus 
acetonitrile:l-propanol (3:l)--recovery of the applied counts was 62%; and 
(3) HPLC on a ubondapak CN column eluted with 0.1 M hexafluoroacetone- 
ammonia, pH 7.1, versus acetonitrile:l-propanol (3:l)--recovery of the 
applied counts was 55%. The overall yield was 6%. The low yield in step 1 was 
due to the use of vinylpyridine to alkylate sulfhydryls. The vinylpyridine- 
derivatized protein precipitated during digestion, although it was in solution in 
0.1 M Tris-C1, pH 8.1, at the start of digestion. 
Amino Acid Analysis. Two commercial laboratories measured the 
amino acid composition of peptides. They were the AAA Labs, Mercer Island, 
Wash., under the direction of Dr. Lowell Ericsson, and the University of 
Michigan Sequencing Facility, Ann Arbor, under the direction of Dr. George 
Tarr. Salt-free peptides were hydrolyzed for 24 hr at 110°C in HC1. Amino 
acids were quantitated by ninhydrin at the AAA Labs or by derivatization 
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with phenylisothiocyanate at the University of Michigan. The latter method 
was developed by Tarr  (1985) and is now marketed by the Waters Co. as the 
"pico-tag" method. The pico-tag method was used for analyses where the 
amount of sample was less than 1 nmol. 
Manual Sequencing. Salt-free peptides were sequenced by Edman deg- 
radation using the manual batch method of Tarr  (1982). PTH-amino acids 
were identified by H P L C  by the method of Black and Coon (1982), in which 
one analysis cycle is completed every 16 min. 
RESULTS 
H P L C  traces of tryptic digests of cholinesterase are shown in Fig. 1, where the 
MP-tryptic peptide is indicated by radioactive counts. In Fig. 1A the 
MP-tryptic peptide from the usual genotype eluted at 49 min. A single 
radioactive peak was obtained. In Fig. 1B the MP-tryptic peptide from the 
atypical-silent genotype eluted at 26 rain. A second radioactive peak eluted at 
the solvent front. This second radioactive peak was not studied because it was 
thought to be monoisopropylphosphate released from the preparation during 2 
years of storage at - 7 ° C ,  or a very short peptide. In Fig. 1C the MP-tryptic 
peptide from the atypical, AA, genotype eluted at 54-59 min. 
The MP-tryptic peptides were purified by two additional H P L C  steps. 
Table I shows the amino acid composition analysis of the usual (UU),  atypical 
Table I. Amino Acid Composition of DFP-Labeled Tryptic Peptides Isolated from Usual (UU), 
Atypical (AA), and Atypical-silent (AS) Variants of Cholinesterase 
Amino acid UU a'b UU c AA c AS ~ 
Ala 3.1 (3) 2.6 (3) 3.1 (3) 3.0 (3) 
Arg 1.0 (1) 0.6 (1) 0 (0) 
Glu 1.2 (1) 1.6 (1) 0.1 (1) 0.9 (1) 
Gly 3.2 (3) 3.6 (3) 3.0 (3) 2.8 (2) 
His 2.1 (2) 1.4 (2) 0.7 (1) 
Leu 5.1 (5) 5.0 (5) 3.9 (4) 
Phe 2.1 (2) 2.0 (2) 1.3 (1) 
Pro 1.0 (1) 1.0 (1) 1.7 (1) 
Ser 7.0 (7) 7.2 (7) 3.8 (5) 1.7 (2) 
Thr 2.3 (2) 1.4 (2) 0.7 (1) 
Val 2.2 (2) 1.9 (2) 2.1 (2) 
Total residues 29 29 22 8 
nmol analyzed 5.0 0.25 0.58 0.45 
i i 
"Values in parentheses were determined from sequence analysis. 
b Method of detection was ninhydrin. 
CMethod of detection was "pico-tag." 
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(AA), and atypical-silent (AS) MP-tryptic peptides. The peptide from the 
usual cholinesterase contained 29 residues, atypical contained 22 residues, 
and atypical-silent contained 8 residues. 
Manual sequence analysis of the usual peptide (Table II) yielded data for 
the first 19 residues. Half of each PTH-amino acid sample was counted, and 
the radioactive counts showed that DFP was attached to serine at the eighth 
position from the N terminal. The radioactive label was not cleaved off during 
Edman degradation to a significant extent. To obtain the complete sequence, 
the MP-tryptic peptide was subfragmented. The peptide was digested with 
chymotrypsin and the subfragments were separated on a C18 #bondapak 
(Waters Co.) column. Sequencing results are in Table III. The data in Table 
III provided important overlapping peptides which aligned the subfragments 
obtained in the following digestion with pepsin. The MP-tryptic peptide was 
subfragmented with pepsin and the subfragments were separated as shown in 
Fig. 2. Sequencing results are given in Table IV. Subfragment P6 was 
analyzed for amino acid composition (Table V) because it contained a 
particularly difficult sequence, Ser-His-Ser. The data established that the 
sequence for the usual genotype was Ser-Val-Thr-Leu-Phe-Gly-Glu-Ser- 
Table II. Manual Sequence Analysis of the DFP-Labeled Tryptic Peptide 
Isolated from Usual Cholinesterase ° 
i 
Edman Assigned Yield of PTH 
cycle amino acid amino acid (pmol) cpm b 
1 Ser 459 8,085 
2 Val 1742 6,842 
3 Thr 660 16,985 
4 Leu 727 9,939 
5 Phe 1828 7,300 
6 Gly 200 6,176 
7 Glu 440 10,566 
8 Ser-[3H]MP - -  568,188 
9 Ala 329 150,204 
10 Gly 806 65,133 
11 Ala 317 27,830 
12 Ala 181 10,419 
13 Ser - -  19,927 
14 Val 257 2,471 
15 Ser - -  7,001 
16 Leu 87 
17 His 148 
18 Leu 50 
19 Leu 49 
aThis peptide was sequenced four times, using 27, 10, 8, and 8 nmol peptide. 
bRadioactivity, expressed as counts per minute (epm), was determined for each PTH-amino acid 
by liquid scintillation counting. 
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Table III. Manual Sequence Analysis of Chymotryptic Subfragments of the Usual 




1 S 2073 G 2143 
2 V2615 E2691 
3 T4063 S 453 
4 L 2167 A 71 







No. of times 1 2 
sequenced 
G1907 A1230 H3415 L1090 L6127 S 6267 
E2067 S1453 L5738 $1347 L6780 L21976 
S-3H-DFP V 728 L5454 P 775 S 5364 F 7256 
A 987 S 102 S 297 G 176 P1744 
G 539 S 76 G 617 
A 549 S 389 
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aThe PTH-amino acid observed by HPLC analysis for each Edman degradation cycle is shown. 
The number that follows each residue is the yield in picomoles. 
Ala-Gly-Ala-Ala-Ser-Val-Ser-Leu-His-Leu-Leu-Ser-Pro-Gly-Ser-His-Ser- 
Leu-Phe-Thr-Arg. 
Sequence analysis (Table VI) of the MP-tryptic peptide isolated from the 
atypical-silent cholinesterase in Fig. 1B showed that the sequence was 
GIy-Glu-Ser-Ala-Gly-Ala-Ala-Ser. Table VI shows that DFP is attached to 
the serine at cycle 3. 
The atypical, AA, MP-peptide was subfragmented by digestion with 




We have isolated and sequenced the DFP-labeled tryptic peptides from three 
genetic types of human serum cholinesterase: the usual (UU), atypical (AA), 
and atypical-silent (AS). Their sequences are compared in Table VIII.  The 
usual cholinesterase yielded a 29-residue peptide which is probably the 
complete tryptic peptide since it terminated in arginine. The 22 residues of 
atypical and 8 residues of atypical-silent exactly matched portions of the 
usual peptide. There were no amino acid substitutions. Of special note was the 
presence of glutamic acid in position 7 from the N terminal in all three 
sequences. This is of interest because Yamato et al. (1983) had suggested that 
atypical cholinesterase contained histidine in place of glutamic acid at this 
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Fig. 2. HPLC of pepsin subfragments of the DFP-labeled 
tryptic peptide isolated from genotype UU cholinesterase. 
The MP-tryptic peptide, containing 26.9 nmol and 
15,200,000 cpm, was dissolved in 10 #1 of 88% formic acid 
and then diluted with 200 #1 of water. Nineteen microliters of 
a freshly prepared pepsin solution, 1 mg/ml, was added. 
Digestion was for 3 hr, 45 min at room temperature. The 
entire sample was injected into a C18 Waters column equili- 
brated with solvent A (0.1% TFA in water). Peptides were 
eluted with a linear gradient increasing in solvent B (acetoni- 
trile containing 0.075% TFA) at a gradient rate of 0.75%/ 
min. The flow rate was 1 ml/min. Seventy-four percent of the 
applied counts were recovered. 
Table IV. Manual Sequence Analysis of the Pepsin Subfragments of the 
Usual DFP-Labeled Tryptic Peptide" 
Edman 
cycle P3 P4 P2 P6 P1 
1 Set 1790 Phe 1075 Val 1376 His 694 Phe 1058 
2 Va12334 Gly 928 Ser 355 Leu 1024 Thr 253 
3 Thr1086 Glu 877 Leu 695 Leu 1081 Arg 372 
4 Leu 2511 Ser-[3H]DFP Ser 571 
5 Ala 1724 Pro 772 
6 Gly 589 Gly 510 
7 Ala 725 Ser 203 
8 Ala 586 His 111 
9 Set 247 Ser 140 
10 Leu 201 
No. of times 2 7 3 3 4 
sequenced 
aThe PTH-amino acid observed by HPLC analysis for each Edman degradation cycle is shown. 
The number that follows each residue is the yield in picomoles. 
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Table V. Amino Acid Composition of Pepsin Subfragment P6 of the 
Usual DFP-Labeled Tryptic Peptide 
Amino acid P6" 
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Gly 1.2 (1) b 
His 1.7 (2) 
Leu 3.0 (3) 
Pro 1.1 (1) 
Ser 3.5 (3) 
Total residues 10 
nmol analyzed 0.83 
aMethod of detection was "pico-tag." 
bValues in parentheses were determined from sequence analysis. 
position. The sequence obtained by Yamato et al. (1983) for the active site of 
usual human serum cholinesterase was Gly-Glu-Ser-Ala-Gly-Ala-Ser-Ala- 
Val-Ser-Leu. In our sequence the order of Ser and Ala in positions 7 and 8 is 
reversed. 
The differences in the lengths of the peptides can probably be attributed 
to protease or peptidase contaminants in the AS and AA cholinesterase 
preparations. Contaminants are suspected because the AS and AA peptides 
were not the result of cleavage by trypsin since they did not terminate in Arg 
or Lys. The identity of the protease contaminant is unknown. Nausch and 
Heymann (1985) demonstrated that dipeptidylaminopeptidase IV can copu- 
rify with cholinesterase. Since this enzyme cleaves two amino acids at a time 
from the N terminal, other contaminants must be responsible for the missing 
amino acids. Five amino acids are presumed missing from the N terminal of 
AS. Seven and 16 amino acids are presumed missing from the C terminals. 
Table VI. Manual Sequence Analysis of the DFP-Labeled Tryptic Peptide Isolated From 
Atypical-Silent Cholinesterase ° 
Edman Assigned Yield of PTH 
cycle amino acid amino acid (pmol) cpm b 
1 Gly 100 6,608 
2 Glu 90 4,185 
3 Ser-[3H]MP 22,966 
4 Ala 92 14,841 
5 Gly 70 7,483 
6 Ala 67 3,595 
7 Ala 60 
8 Ser 224 
"This peptide was sequenced three times, using 122, 100, and 75 pmol peptide. 
bRadioactivity, expressed as counts per minute (cpm), was determined for each PTH-amino acid 
by liquid scintillation counting. 
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Table VII. Manual Sequence Analysis of the Pepsin Subfragments of the Atypical 
DFP-Labeled Tryptic Peptide a 
Edman cycle 
1 Ser 507 Phe 1111 Val 848 His 192 
2 Val 1536 Gly 668 Ser 264 Leu 340 
3 Thr 502 Glu 693 Leu 419 Leu 355 
4 Leu 938 Ser-[3H]MP Ser 45 
5 Ala 488 Pro 244 
6 Gly 448 Gly 196 
7 Ala 335 
8 Ala 403 
9 Ser 191 
No. of times 1 2 2 2 
sequenced 
aThe PTH-amino acid observed by HPLC analysis for each Edman degradation cycle is shown. 
The number that follows each residue is the yield in picomoles. 
As the complete tryptic peptide was not obtained from the atypical 
variant, one might argue that an amino acid substitution might be present in 
the missing seven residues. Our work does not rule out this possibility, but 
neither does it support it. Our results explain how DFP-labeled peptides from 
atypical and usual cholinesterases can have different solubilities, charges, and 
mobilities and still contain no amino acid substitutions. This leaves no reason 
for expecting the location of an amino acid alteration to be in the DFP-labeled 
peptide of atypical cholinesterase, as opposed to any other region in the 580 
amino acid subunit. The mutation might be anywhere in the linear sequence, 
although in a three dimensional projection we expect it to be approximately 5 
A from the active-site serine. This expectation is based on the estimated 
distance between the anionic-site and the active-site serine (Wilson and Quan, 
1958). 
The atypical-silent eholinesterase molecule contains two genetically 
different subunits. It contains atypical subunits and silent subunits. It is likely 
that the DFP-labeled peptide from our AS sample originated from atypical 
Table VIII. Active-Site Sequences for Usual, Atypical, and Atypical-Silent 
Human Cholinesterase Genotypes 







~The * denotes site of DFP binding. 
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subunits alone. Evidence for this conclusion comes from the stoichiometry of 
DFP binding which was calculated for our DFP-labeled, aged, cholinesterase 
preparations. Two AS samples bound 0.31 and 0.33 mol of DFP/mol of 
subunit. Two UU samples bound 0.80 and 0.76 mol of DFP/mol of subunit. 
The label had been aged so one would expect less than one equivalent bound 
per subunit. The significantly lower stoichiometry for DFP binding in the AS 
samples, compared to the UU samples, suggests that the silent subunits did 
not bind DFP. This is not surprising since silent cholinesterase from some 
donors has zero activity (Liddell et al., 1962). Silent cholinesterase from other 
donors has been reported to have 1 to 3% of normal activity (Altland and 
Goedde, 1970; Rubinstein et al., 1970) and therefore may be expected to bind 
DFP. 
The single DFP-labeled peptide we observed is consistent with other 
evidence (Lockridge et al., 1979) that the four subunits of cholinesterase are 
identical. 
The active-site peptide is highly unusual in its high content of serine and 
threonine, which total 9 residues of 29. Since PTH-serine and PTH-threonine 
were obtained in a low yield from Edman degradation, the active-site peptide 
was difficult to sequence and had to be subfragmented to get the complete 
sequence. 
The active-site tryptic peptide of acetylcholinesterase isolated from the 
electric organ of Torpedo californica is Thr-Val-Thr-Ile-Phe-Gly-Glu-Ser- 
Ala-Gly-Gly-Ala-Ser-Val-Gly-Met-His-Ile-Leu-Ser-Pro-Gly-Ser-Arg (Mac- 
Phee-Quigley et al., 1985). There is a remarkable degree of homology with the 
human serum cholinesterase active-site peptide, as 17 of 24 residues are 
identical, and 3 are conservative substitutions. The active-site peptide from 
horse serum cholinesterase (Jansz et al., 1959), Phe-Gly-Glu-Ser-Ala-Gly- 
(Ala-Ala-Ser), is identical to a portion of the peptide from human serum 
cholinesterase. 
The results reported here provide the longest sequence information 
available to date for a cholinesterase of human origin. This should help to 
distinguish human butyrylcholinesterase from acetylcholinesterase when 
these are isolated as DNA clones and should, therefore, be useful to the 
cloning work already in progress in various laboratories. 
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